Wegovy Compounding Legal Status: What Patients and Prescribers Need to Know in 2025
A guide to the FDA approval history, compounding legal status, label requirements, and post-market safety data for Wegovy (semaglutide 2.4 mg).
WEGOVY: Regulatory History
6 source-based articles maintained by the HealthRX.com Editorial Team.
6articles
4topic areas covered
Jul 10, 2025latest review
WEGOVY: Regulatory History library
Showing 6 of 6 clinical reviews.
Wegovy FAERS Safety Signals: What Post-Market Surveillance Data Actually Show
An evidence-based review of Wegovy (semaglutide 2.4 mg) safety signals reported to the FDA Adverse Event Reporting System (FAERS), including GI events, pancreatitis, thyroid neoplasms, and gallbladder disorders.
Wegovy FDA Approval History: Timeline, Label Changes, and Safety Updates
The Wegovy FDA label covers three indications: adult weight management (BMI ≥30 or ≥27 with a comorbidity), ages 12+, and cardiovascular risk reduction.
Wegovy Global Regulatory Status: FDA Approval, EMA Authorization, and Worldwide Access in 2026
Wegovy (semaglutide 2.4 mg) prescribing information: FDA approved June 4, 2021; EMA authorized January 6, 2022; cardiovascular indication added March 2024.
Wegovy Legal and Patent Challenges: FDA History, Litigation, and Market Exclusivity
A clinical review of Wegovy's regulatory path, patent disputes, legal challenges from compounding pharmacies, and the evolving FDA label for semaglutide 2.4 mg.
Wegovy Pipeline and Next-Gen GLP-1 Therapies: What Comes After Semaglutide 2.4 mg
A clinical review of the Wegovy regulatory timeline, current label, post-market safety data, and the next-generation GLP-1 and multi-agonist drugs in development that may succeed semaglutide 2.4 mg.